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Patrick M. Honore* and Herbert D. SpapenSee related research by Wan et al., http://ccforum.biomedcentral.com/articles/10.1186/s13054-016-1207-7Ulinastatin is a protease inhibitor derived from human
urine with strong anti-inflammatory and anticoagulant
activity [1]. Besides its potential to protect tissues against
neutrophil-mediated injury, ulinastatin is also antici-
pated to benefit patients undergoing cardiopulmonary
bypass (CPB) surgery by preventing or attenuating post-
pump organ injury. Wan et al. recently showed that uli-
nastatin, given as a 500,000 IU bolus after induction of
anesthesia, was associated with a lower incidence of
acute kidney injury (AKI) and less need for renal re-
placement therapy (RRT) after cardiac surgery [2]. This
study certainly fills a gap because “renal failure” was
barely documented before as a postoperative complica-
tion in this patient population [3]. Although data are
convincing and shortcomings neatly discussed, we feel
that some important aspects remain underexposed. First,
the authors do not comment on peri-operative fluid ad-
ministration. AKI was defined according to the Kidney
Disease Improving Global Outcomes criteria using
serum creatinine (SCr) but not urine output as a key de-
terminant. SCr, however, has poor specificity and sensi-
tivity for identifying incipient AKI. AKI misclassification
may indeed result from flawed estimation of baseline
SCr or changes in SCr concentrations due to shifts in
fluid balance. For instance, ample fluid loading in the
immediate post-operative period after CPB surgery may
“dilute” creatinine concentrations and thus mask AKI.
Second, mean arterial pressure (MAP) and transfusion
amount are independent risk factors for postoperative
AKI in cardiac surgery patients [4]. No information is
provided with regard to incidence or duration of any ep-
isodes of hypotension in either study groups despite
MAPs that were near the “critical” 60 mmHg perfusion* Correspondence: Patrick.Honore@az.vub.ac.be
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tended to receive more red blood cell transfusion.
Avoidance of transfusion, especially when hemoglobin
levels exceed 8 g/dL, is known to lower the risk for de-
veloping AKI in patients undergoing CPB surgery [4].
Third, patients in the treatment group required less RRT
but had higher mortality, suggesting that the higher inci-
dence of RRT in controls might reflect severity of illness
rather than occurrence of AKI. Finally, a very recently
published large controlled trial in patients undergoing
elective valve replacement with CPB could not confirm a
renal protective effect of ulinastatin [5]. Also, before
promoting a more widespread use of ulinastatin, its
effects in a predominantly non-Asian population as
well as a standard dosing guideline should be better
established.
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